Guru Fundamental Report for UNH

Validea's guru fundamental report rates UnitedHealth Group (UNH) at 77% using the Martin Zweig Growth Investor model, placing it just below the threshold for 'some interest' based on the strategy's criteria. While UNH passes tests for P/E ratio, sales growth, and long-term EPS growth, it notably fails on revenue growth in relation to EPS growth, earnings growth rate over several past quarters, and current quarter EPS growth relative to its historical rate. This assessment, derived from a strategy with a strong historical outperformance record, highlights both strengths and specific areas of concern for the large-cap insurance stock's fundamental growth profile.

Analysis

UnitedHealth Group (UNH) presents a mixed but fundamentally sound profile according to Validea's Martin Zweig-based growth model, achieving a score of 77%, which is just below the 80% threshold indicating strategic interest. The company demonstrates strength in several key areas, passing tests for its P/E ratio, overall sales growth rate, earnings persistence, and long-term EPS growth, suggesting a reasonable valuation and a solid underlying business. Furthermore, UNH shows positive current-quarter earnings momentum relative to both the prior year and the preceding three quarters, and it passes the screen for insider transactions, a positive confidence signal. However, the analysis flags critical weaknesses for a growth-oriented strategy. Notably, the company fails on the metric comparing revenue growth to EPS growth, implying that earnings expansion may not be fully supported by top-line acceleration. It also fails on the earnings growth rate for the past several quarters and on the current quarter's EPS growth relative to its historical rate, indicating a potential deceleration in growth momentum, which is a primary concern for the Zweig model.

Key Decisions for Investors

• Growth-focused investors should treat the 77% score as a signal for caution, as the model highlights a deceleration in earnings momentum and a disconnect between revenue and EPS growth.
• Investors with a 'Growth at a Reasonable Price' (GARP) approach may find the combination of a passing P/E ratio, positive insider activity, and strong long-term EPS prospects to be compelling, despite the recent lack of acceleration.
• Shareholders should closely monitor upcoming earnings reports to see if the company can re-accelerate its sequential earnings growth and better align its top-line performance with its EPS expansion, as these are the primary weaknesses identified.